AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

The Armed Forces Radiobiology Research Institute (AFRRI) and NIAID have finalized the design of the PBI-BM2.5 protocol to evaluate Valion Bio's Entolimod for GI-ARS, meeting FDA Animal Rule criteria. This proprietary murine model isolates GI pathophysiology to generate the high-quality non-clinical efficacy data required for potential licensure under the FDA's Animal Rule.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.